NCT04527666

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Conditions

• Gastroesophageal Varices
• JAK2 Mutation
• Myeloproliferative Neoplasm

Interventions

Type	Name	Description
DRUG	Anticoagulation Agents	Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-09-30
• Completion: 2022-09-30
• First posted: 2020-08-26
• Last updated: 2020-08-27